Table 3.

Risks of glioma associated with folate metabolism polymorphisms

HistologyGene and SNPGenotypeCases (%)Controls (%)OR (95% CI)Ptrend
AllMTHFR
A1298C (rs1801131)AA450 (44.8)512 (50.7)1.00 (reference)0.06
AC457 (45.5)396 (39.2)1.32 (1.09-1.58)*
CC97 (9.7)102 (10.1)1.08 (0.80-1.47)
AC + CC554 (55.2)498 (49.3)1.27 (1.06-1.51)*
MTHFR
C677T (rs1801133)CC491 (49.0)466 (46.1)1.00 (reference)0.26
CT414 (41.3)441 (43.7)0.89 (0.74-1.07)
TT98 (9.8)103 (10.2)0.90 (0.66-1.22)
CT + TT512 (51.0)544 (53.9)0.89 (0.75-1.06)
MTRR
A66G (rs1801394)AA333 (33.1)343 (33.9)1.00 (reference)0.75
AG487 (48.5)484 (47.9)1.04 (0.85-1.26)
GG185 (18.4)184 (18.2)1.04 (0.80-1.34)
AG + GG672 (66.9)668 (66.1)1.04 (0.86-1.25)
MTR
A2756G (rs1805087)AA650 (64.7)654 (64.8)1.00 (reference)0.91
AG320 (31.8)317 (31.4)1.02 (0.84-1.23)
GG35 (3.5)39 (3.9)0.90 (0.57-1.44)
AG + GG355 (35.3)356 (35.2)1.00 (0.84-1.21)
GlioblastomaMTHFR
A1298C (rs1801131)AA198 (44.4)512 (50.7)1.00 (reference)0.19
AC209 (46.9)396 (39.2)1.37 (1.08-1.73)*
CC39 (8.7)102 (10.1)0.99 (0.66-1.48)
AC + CC248 (55.6)498 (49.3)1.29 (1.03-1.62)*
C677T (rs1801133)CC211 (47.4)466 (46.1)1.00 (reference)0.99
CT184 (41.3)441 (43.7)0.93 (0.73-1.18)
TT50 (11.2)103 (10.2)1.07 (0.74-1.57)
CT + TT234 (52.6)544 (53.9)0.96 (0.76-1.20)
MTRR
A66G (rs1801394)AA149 (33.3)343 (33.9)1.00 (reference)0.52
AG208 (46.5)484 (47.9)0.98 (0.76-1.27)
GG90 (20.1)184 (18.2)1.13 (0.82-1.55)
AG + GG298 (66.7)668 (66.1)1.02 (0.81-1.30)
MTR
A2756G (rs1805087)AA291 (65.1)654 (64.8)1.00 (reference)0.60
AG145 (32.4)317 (31.4)1.03 (0.81-1.31)
GG11 (2.5)39 (3.9)0.64 (0.32-1.26)
AG + GG156 (34.9)356 (35.2)0.99 (0.78-1.25)
AstrocytomaMTHFR
A1298C (rs1801131)AA158 (48.0)512 (50.7)1.00 (reference)0.56
AC139 (42.2)396 (39.2)1.14 (0.88-1.49)
CC32 (9.7)102 (10.1)1.02 (0.66-1.58)
AC + CC171 (52.0)498 (49.3)1.12 (0.87-1.44)
C677T (rs1801133)CC163 (49.5)466 (46.1)1.00 (reference)0.20
CT138 (41.9)441 (43.7)0.88 (0.68-1.15)
TT28 (8.5)103 (10.2)0.77 (0.49-1.22)
CT + TT166 (50.5)544 (53.9)0.86 (0.67-1.11)
MTRR
A66G (rs1801394)AA112 (34.0)343 (33.9)1.00 (reference)0.92
AG157 (47.7)484 (47.9)1.00 (0.76-1.32)
GG60 (18.2)184 (18.2)0.98 (0.68-1.41)
AG + GG217 (66.0)668 (66.1)1.00 (0.77-1.30)
MTR
A2756G (rs1805087)AA208 (63.2)654 (64.8)1.00 (reference)0.46
AG104 (31.6)317 (31.4)1.03 (0.78-1.35)
GG17 (5.2)39 (3.9)1.34 (0.74-2.42)
AG + GG121 (36.8)356 (35.2)1.07 (0.82-1.38)
OligodendrogliomaMTHFR
A1298C (rs1801131)AA42 (39.6)512 (50.7)1.00 (reference)0.11
AC54 (50.9)396 (39.2)1.71 (1.12-2.63)*
CC10 (9.4)102 (10.1)1.22 (0.59-2.52)
AC + CC64 (60.4)498 (49.3)1.61 (1.07-2.43)*
C677T (rs1801133)CC53 (50.0)466 (46.1)1.00 (reference)0.35
CT42 (39.6)441 (43.7)0.77 (0.50-1.19)
TT11 (10.4)103 (10.2)0.85 (0.43-1.69)
CT + TT53 (50.0)544 (53.9)0.79 (0.53-1.18)
MTRR
A66G (rs1801394)AA30 (28.3)343 (33.9)1.00 (reference)0.97
AG62 (58.5)484 (47.9)1.41 (0.89-2.24)
GG14 (13.2)184 (18.2)0.87 (0.45-1.69)
AG + GG76 (71.7)668 (66.1)1.27 (0.81-1.98)
MTR
A2756G (rs1805087)AA66 (62.3)654 (64.8)1.00 (reference)0.92
AG38 (35.8)317 (31.4)1.12 (0.73-1.72)
GG2 (1.9)39 (3.9)0.50 (0.12-2.14)
AG + GG40 (37.7)356 (35.2)1.06 (0.70-1.60)